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1. Introduction   
Toxoplasmic encephalitis (TE), a life-threatening disease in HIV/AIDS infected individuals, 
is an inflammation of the brain caused by the reactivation of latent infection of the protozoa 
Toxoplasma gondii. Immunocompetent host when infected with T. gondii is almost always 
unnoticeable or develops mild and non-specific signs and symptoms, then tissue cysts are 
the consequence harbored in those infected persons life-long, quietly without any problem. 
However, when host immunity is suppressed by any cause but mostly by HIV/AIDS, the 
previously quiescent protozoa become active and the aggressive stage, tachyzoite, causes 
severe clinical manifestations in the Central Nervous System (CNS) such as encephalitis or 
abscess. 
In the early 1980s, at the beginning of AIDS pandemic, there were many alarming case-
reports threatening the world medical community with increasing numbers of unknown 
causes and severe diseases presented in homosexual men, hemophiliacs and Haitian. TE 
was one of the most common opportunistic infections of this immunocompromised host. 
Huge efforts have been put on to combat with TE including budget, manpower and research 
on diagnostic methods, prophylaxis, treatment and prevention. The incidence of TE is now 
decreasing due to primary and secondary prophylaxis as well as immune restoration 
because of the HAART (Highly active antiretroviral therapy), but some old problems still 
exist and new ones have surfaced.  
This chapter will focus on all aspects of TE including the etiologic organism, epidemiology, 
clinical manifestations, diagnostic methods, management and outcome as well as 
prophylaxis and prevention. Evidences from our research on T. gondii and literature review 
will be used as an input. With those frameworks, an extensive perspective on this 
fascinating disease will be forthcoming. 
2. Etiologic organism: Toxoplasma gondii  
T. gondii was discovered since 1908 simultaneously by 2 groups of researchers. Firstly, 
Charles J. H. Nicolle (1866-1936) and Louis H. Manceaux (1865-1943) from the Pasteur 
Institute in Tunisia isolated a new parasite from the African rodent, Ctenodactylus gundi, and 
differentiated it from Leishmania. Secondly, the Italian researcher namely Alfonso Splendore 
(1871-1953) who worked at Sao Paulo, Brazil identified this protozoan from the liver of 
rabbit (Dubey et al., 1970;  Sukthana, 2006). T. gondii was named a year later by Nicolle and 
Manceaux according to its bow-like shape (Toxoplasma is from a Greek word: toxos means 
bow or arc; plasma means life) and gondii may result from a misspelling of the scientific 
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name of its original host, the gundii (Ferguson, 2009a). The first congenital case of 
toxoplasmosis was described in 1923 and the first adult case was diagnosed in 1940 (Frenkel 
& Fishback, 2000). It was not until 1969 when its life cycle was completely known with cats 
and other felids as the only definitive host in which sexual reproduction takes place to 
produce infective oocysts. Human, warm-blooded domestic animals, birds, and rodents 
including wild and marine mammals are intermediate hosts that harbor tissue cysts in their 
bodies (Hutchison et al., 1969; Dubey et al., 1970; Dubey, 2007; Ferguson, 2009b). T. gondii 
was classified as coccidian belonging to the phylum Apicomplexa which is an intracellular 
organism (Dubey et al., 1970).  
2.1 Life cycle and mode of transmission of T. gondii  
There are 3 infective stages of T. gondii i.e. 1) oocysts produced and shed by cat and felid 
animals, 2) an active, rapidly dividing tachyzoite form and 3) an inactive dormant 
bradyzoite harbored in tissue cysts. Tachyzoite and bradyzoite, sized 2 x 9 µm, cannot be 
differentiated by light microscope, while the mature oocyst is an oval shape, sized 9 x 13 µm 
containing 2 sporocysts with 4 sporozoites in each.  
 
 
Fig. 1. Life cycle of Toxoplasma gondii: Cat and felids are only definitive host where T. gondii 
completes its life cycle. Intermediate hosts are human, warm-blooded domestic animals, 
bird and rodent including wild and marine mammals. Immature oocysts develop in the 
environment before becoming infected mature oocysts. Acute stage of infection occurs in 
both definitive and intermediate hosts, but turns to be chronic and develops as a tissue cyst 
in the intermediate host. Sexual reproduction occurs in cat producing immature oocysts. 
When mature oocysts are ingested by hosts, sporozoites are released after exposure to 
gastric enzymes and invade enterocytes, whereas in asexual multiplication, multiple 
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fissions, occurs resulting in many tachyzoites causing cell rupture and subsequently they 
invade other enterocytes producing the active stage of infection (Figure 1). In intermediate 
host tachyzoites will shortly transform to be inactive bradyzoites and reside silently in tissue 
cyst for the whole life of the infected host. Thus the chronic stage of infection occurs. On the 
contrary, tachyzoites in definitive host modify to be macrogametocyte and microgametocyte 
and sexual reproduction occurs producing immature oocysts which when shed with cat’s 
fecaes, need about 2-5 days to develop in the environment until mature as infective stage. 
Toxoplasma is transmitted to human by 3 routes. The most common two are ingesting 
contaminated food or water with mature oocysts and consuming undercooked, infected 
meat where bradyzoites harbor in tissue cysts. The least frequent route is transplacental 
transmission which occurs only when the mother acquires primary infection during 
pregnancy. A European multicenter study including cities in Western Europe identified the 
consumption of undercooked meat as the strong risk factor for acquiring a T. gondii 
infection, whereas in Central and South America it is related with large numbers of stray 
cats that have access to the outdoor environment of which the climate favours and prolongs 
the survival of oocysts (Sukthana, 2006). Toxoplasmosis transmitted by cat excreta is not 
straight forward in Southeast Asia. Due to the religious belief, Malaysian and Indonesian 
Muslims prefer cats to dog as pet, while lots of stray cats are left in Buddhist temples in 
Thailand. Those settings should promote cat’s excreta as a strong risk factor in that region. 
Noteworthy, human Toxoplasma seroprevalence in Thailand is much lower than in those two 
countries (21.9% vs. 44.8% and 58%) and correlated with cat seroprevalence (Konishi et al., 
2000; Nissapatorn et al, 2004a; Sukthana, 2006). This might be due to high humidity and 
more rainfall in the latter countries suggesting that ground temperature is an important 
determinant of oocyst survival. 
3. Epidemiology and risk factor  
About 20% to 40% of individuals with AIDS develop TE from the reactivation of a latent T. 
gondii infection when the CD4 cell count falls below 100/mm3 (Luft & Remington, 1992; 
Sukthana, 2000; Ajzenberg, 2009). The incidence of TE is thus directly proportional to the 
prevalence of antibodies to Toxoplasma in any given population. Before the advent of 
HIV/AIDS epidemic in 1981, toxoplasmosis was occasionally reported in 
immunocompromised patients, mostly in those with malignancies of the reticuloendothelial 
system and cardiac transplant recipients with lesions mostly outside the CNS. But, TE has 
become one of the commonest causes of focal brain lesions in Western Europe and North 
America due to AIDS pandemic (Luft & Remington, 1988). Since then, more and more TE 
cases in HIV/AIDS individuals were diagnosed worldwide. Nearly three decades from that 
point, nowadays to get a clearer picture of its epidemiology and clinical course, herein, three 
periods could be divided as: 1) TE during the beginning of AIDS pandemic period (1980s), 
2) TE during prophylaxis period (1990s) and 3) TE during HAART period (1997-present). 
3.1 TE during the beginning of AIDS pandemic period (1980s) 
At the beginning of the 1980s, more and more of the mysterious cases with severe 
manifestations and fatal outcomes presented in homosexual men, hemophiliacs and Haitian. 
HIV was subsequently identified as the cause that impaired host immunity causing acquired 
immunodeficiency syndrome (AIDS) and opportunistic infections. In November 1982, the 
Centers for Disease Control (CDC) reported 19,744 AIDS cases from the United States, with 
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287 deaths and 54 cases have been reported from foreign countries (Gapen, 1982). 
Neurological involvement was seen in three out of four AIDS patients and TE was one of the 
most common neurological complications. Luft and colleagues (1983) reported acute 
encephalitis caused by Toxoplasma in 10 patients from Belgium, USA and Canada who had 
no underlying history associated with toxoplasmosis. All patients had a prodrome which 
varied from one week to 18 months. Three patients had disseminated toxoplasmosis with 
several organs affected (Table 1). Half of them had concomitant infections including 
tuberculosis, pneumocystosis, cytomegalovirus infection (CMV) and candidiasis. Other 
studies revealed similar pictures which reported neurological complications ranging from 
20% to 41% with TE as the most or the second most common neurological disorders in 
HIV/AIDS patients (Luff, et al, 1983; Levy, et al, 1985; Berger, et al, 1987).  
A 10-year observational studies from USA (Luft, & Castro, 1991; Richards et al, 1995) 
revealed at the end of 1989, there were 5,614 cases of toxoplasmosis reported to the CDC as 
the AIDS indicator disease and it increased to 14,059 (5.1%) of 274,150 adults and 
adolescents in the United States. The risk factors were observed as black male, intravenous 
drug users (IVDU), homosexual men, immigrants, Haitian and different geographic 
location. Richards and colleagues demonstrated that TE was more common among black 
males than white (5.2% vs. 4.2%, P < .0001) and was also more common among IVDU than 
among men with male sex partners (5.9% vs. 4.6%, P < .0001). Immigrants to the USA from 
Africa, Latin America and Haiti were three to four times more likely to develop TE than 
American-born (Luft, & Castro, 1991). The rate of TE was higher in the northeastern and 
southern states of America (5.6% vs. 5.5%) than in the north-central and western states (4.4% 
vs. 4.1%, P < .0001) this was related to the Toxoplasma IgG seroprevalence which was 
observed twice higher in the northern and northeastern regions than those in the western 
and southwestern regions (Richards et al, 1995).  
In Africa, Europe, and South America, where the prevalences of chronic T. gondii infection 
were as high as 60%-75%, patients with AIDS who developed TE were three to four times 
greater than that in the United States whereas HIV-infected adults with latent T. gondii 
infection was less than 40%, only one-third of those patients developed TE (Luft & 
Remington, 1992). In France, 11% of AIDS-defining illness was due to TE in 1987, and rose to 
23% in 1992 (Oksenhendler et al, 1994). Studies from France and Brazil in 1985 to 1990 
reported the prevalence of TE in AIDS patients at 17% and 13% by presumptive diagnosis 
compared with 22% by definite diagnosis, respectively (Ragnaud et al, 1993; Wainstein et al, 
1993). In Asia, the seroprevalence of toxoplasmosis was low, from 4% to 42.5% in Japan, 
Korea, Taiwan and Thailand, but was higher in India, Malaysia and Indonesia as 22.4% to 
67.8% (Nissapatorn, 2009). The first documented case of TE reported in an international 
journal was from Thailand in 1992 (Sukthana, 2000), but a report in a local textbook showed 
9.7% of cerebral toxoplasmosis as AIDS-defining illnesses from 1987 to 1994 and increased 
to 10.5% in 2001 and to 14.8% in 2002 (Chankrachang, 2004).   
3.2 TE during prophylaxis regimen period (1990s)  
In the 1990s, numerous TE cases as one of the common opportunistic infections in 
HIV/AIDS individuals were being diagnosed; medical researchers thus developed a clearer 
picture of its epidemiology and clinical features. For example, the incidence of TE was 
found to be 20.5 per 100 patient-years in France (Bossi et al., 1998), 15.9 per 100 patient-years 
in Swiss HIV Cohort study group (Furrer et al, 1999) and 4.0 per 100 patient-years in nine 
US cities (Jones et al, 1996). Khetsuriani and colleagues (Khetsuriani et al, 2002) studied the 
 
www.intechopen.com
 
Toxoplasmic Encephalitis 
 
285 
Study 
period 
[References] 
Study 
Location 
Patients Risk factors TE 
Prevalence 
Clinical 
features 
Diagnostic 
procedures 
1981-1982  
[Luft et al, 
1983] 
Research 
Institute, 
Palo Alto 
Medical 
Foundation, 
USA   
10 patients 
with acute 
encephalitis 
from 
Belgium, USA 
and Canada 
Host 
immune 
deficiency 
by 
unknown 
cause in 
homosexual 
men, IVDU 
and 
Haitians. 
All developed 
TE with 
disseminated 
toxoplasmosis 
1wk-18 mo 
prodromic 
period  
Brain 
involvement 
with other 
organs 
affected such 
as lung, retina 
and heart 
Serology (IgG 
and all 
negative IgM) 
Mice 
inoculation 
1980-1984 
[Berger et al, 
1987] 
Jackson 
Memorial 
Hospital, 
Miami, 
Florida, USA
132 AIDS 
patients with 
symptomatic 
AIDS 
(including :     
55%Haitian, 
27%homo-
sexual men 
and 
11%IVDU ) 
Haitian  39% Fever 
Headache 
Alteration of 
semsorium 
Hemiparesis 
Ataxia 
Histological 
diagnosis by 
Biopsy or 
Autopsy 
Immuno-
peroxidase 
staining  
CT showing 
multiple 
enhanced 
ring-shaped 
lesions 
1985-1990 
[Ragnaud et 
al, 1993] 
Bordeaux 
Regional 
Hospital, 
France 
428 AIDS 
patients with 
initial CD4= 
72 cell/mm3 
M:F= 2.8:1 
Mean age 
36.2 yrs  
43% homo-
sexual men
30% IVDU 
17% 62% focal 
neurological 
deficit 
58% fever 
47%headache
45% altered 
consciousness
18% seizures 
CT findings:  
focal mass 
60% with and 
40% without 
ring 
enhancement 
59% multiple 
lesions 
58% with 
brain edema 
1985-1999 
[Wainstein 
et al, 1993] 
Hospital  de 
Clinicas de 
Porto 
Alegre, 
Brasil 
516 AIDS 
patients 
- 13% by 
presumptive 
diagnosis         
and 22% by 
definite 
diagnosis  
 
Fever with 
92% sen and 
56% spec 
Neurological 
focal signs 
with 59% sen 
and 82% spec 
Headache 
with 41% sen 
and 69% spec
65% by blood 
serology with 
95% sen and 
30% spec 
49% by CSF 
serology with 
77% sen and 
56% spec 
By CT with 
65% sen and 
82% spec 
125 patients 
by Autopsy 
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Study 
period 
[References] 
Study 
Location 
Patients Risk factors TE 
Prevalence 
Clinical 
features 
Diagnostic 
procedures 
1981-1990 
[Richards    
et al,1995] 
San 
Francisco, 
USA 
Homosexual 
men,  with 
AIDS 
IVDU, 
Homo-
sexual men, 
Black male,  
geographic 
difference 
0.05 
cases/perso
n-year of 
observation 
- - 
Table 1. Summary of the data from studies on epidemiology and clinical course of 
toxoplasmic encephalitis (TE) during the beginning of AIDS pandemic period (1980s). IVDU 
= Intravenous drug user, mo = month(s), sen = sensitivity, spec = specificity, wk = week(s). 
burden of encephalitis in USA from 1988 to 1997 and revealed TE accounted for the majority 
of 34.1% known causes of hospitalization due to encephalitis (21,504 hospitalizations; SE, ± 
2,583). More than 97% of TE had been reactivated from the chronic quiescent Toxoplasma 
infection, nevertheless, few TE cases developed as acute infection (Richards et al, 1995). 
Only 30%-50% of HIV-positive patients with chronic T. gondii infection developed TE when 
their immune system became severely compromised. These were because host factors or 
virulence among different strains of Toxoplasma played a role in predisposing those patients 
to recrudescence of active clinical symptoms and signs (Luft & Remington, 1992). The 
research questions in that period was focused on when and what caused the reactivation to 
occur and how patients could be taken care of.  
There were various retro- and prospective studies on the prevalence of TE, risk factors and 
prophylaxis worldwide (Table 2). To combat aggressive opportunistic infections (OIs) in 
HIV/AIDS patients including PCP, CMV infection and toxoplasmosis, medical researchers 
have unanimously agreed in giving primary prophylaxis to the population at risk of those 
OIs in suitable time. Primary prophylaxis should be given to prevent OIs when immune 
deficiency occurs and secondary prophylaxis would be continuously prescribed after acute 
opportunistic infections subsided. In general, HIV/AIDS individuals were mostly 
prescribed penthamedine, cotrimoxazole and dapsone as the prophylaxis of PCP and CMV 
infection which were more aggressive and occurred earlier than toxoplasmosis, when their 
CD4 were < 200 cell/mm3. The matters had arisen whether those medications were also 
preventing TE and were good candidate regimens of appropriate dosage with acceptable 
adverse effect and adherence or compliance of the patients. In the case of TE, there were two 
things to be considered for primary prophylaxis which were HIV/AIDS infected person 
who was also seropositive of T. gondii antibody and CD4 was lower than 100 cell/mm3 
(Oksenhendler et al, 1994; Richards et al, 1995; Leport et al, 1996).  
Table 2 summarized the data from studies which were carried out in the 1990s concerning 
TE epidemiology, prophylaxis regimens and outcomes. Cotrimoxazole or trimethoprim-
sulfamethoxazole (TMP-SMZ) was the most popular regimen for TE primary prophylaxis, 
while Fansidar (pyrimethamine-sulfadiazine) was prescribed at the beginning of 1990 when 
CD4 was lower than 200 cell/mm3 (Carr et al, 1992; Köppen et al, 1992). However, it was not 
recommended for the primary prophylaxis of TE because of its side-effects especially rash 
and allergy. Thus patients discontinued the prophylaxis and had higher TE reactivation. 
Pyrimethamine had bone marrow toxicity. When patients received without leucovorin 
supplement the survival rate reduced (Jacobson et al, 1994). Even though pyrimethamine 
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was not recommended as a first-line regimen for primary prophylaxis of TE, some medical 
researchers considered pyrimethamine for patients who were intolerant to TMP-SMZ, 
especially in high risk patients with  CD4 <100 cell/mm3 (Leport et al, 1996). 
TMP-SMZ was the drug of choice for prophylaxis for both PCP and toxoplasmosis (Carr et 
al, 1992; Richards et al, 1995). Therefore, there were various regimens ranging from 1 
double-strength1 (DS) tablet twice daily to 1 DS tablet 3 times weekly (14 DS tablets to 3 DS 
tablets per week) have been used. Ribera and colleagues (1999) found that since 1992, 
patients received either one of the following 5 regimens of TMP-SMZ for TE prophylaxis 
i.e.1 DS tablet daily (7DS tab/wk), 2 DS tablets daily 3 times weekly (6 DS tab/wk), 1 DS 
tablet 5 times weekly (5 DS tab/wk), 1 DS tablet 3 times weekly (3 DS tab/wk), and 1 single-
strength (SS) tablet daily (3.5 DS tab/wk), they noticed the more frequent doctors began 
prescribing low doses of TMP-SMZ the higher number of patients receiving TMP-SMZ 
prophylaxis developed TE. Therefore, they studied to assess the efficacy of the various doses 
of TMP-SMZ as primary prophylaxis for TE and concluded that patients receiving low dose 
TMP-SMZ (<4 DS tab/wk) had a higher risk of developing TE than those who received high 
dose TMP-SMZ indicating 89% protective efficacy for high doses. An insufficient 
concentration of the low dose TMP-SMZ within the CNS may be an additional problem in 
the prevention of toxoplasmosis. Moreover, they also studied the potential interactions 
between rifampin and TMP-SMZ and hypothesized that rifampin may reduce the efficacy of 
TMP-SMZ.  
Dapsone combined with pyrimethamine (200/75 mg once weekly) was more effective in the 
primary prophylaxis of TE than aerosolized pentamidine (300 mg every 4 weeks) and had 
the advantage of a lower cost and easier administration (Torres et al, 1993; Opravil et al, 
1995). Girard and colleagues (1993) revealed dapsone plus pyrimethamine prevented first 
episodes of TE better, but they were more toxic than aerosolized pentamidine (42 patients 
discontinued dapsone plus pyrimethamine while only 3 patients stopped aerosolized 
pyrimethamine, p<0.001) 
In conclusion, primary prophylaxis was the important strategy to prevent TE occurrence in 
the 1990s period. TMP-SMZ was the drug of first choice which was prescribed when 
HIV/AIDS seropositive to T. gondii antibody had low CD4 <200 cell/mm3. By this practice, 
the prevalence of TE was reduced from 19% in 1988 to 6% in 1994 (Katlama, 1995). The 
incidence of TE was 3.9 cases/100 person-years (95% CI, 3.7–4.1 cases/100 person-years), 
patients who discontinued TMP-SMZ increased the risk of TE (Abgrall et al, 2001). 
3.3 TE during HAART period (1997-present)  
Since 1997, protease inhibitor, an antiretroviral drug, had been widely available, HIV-
infected persons have lived longer and healthier lives. Since then, in the period of 15 years, 
that development was considered one of the great success stories of modern medicine. The 
death rate from HIV disease was reduced by 50 to 80% and changed from a fatal and 
hopeless illness to what is now a manageable chronic disease. The simultaneous 
combination of three or more different antiretroviral drugs was known as Highly Active 
Antiretroviral Therapy or HAART (Cooper 1996). It significantly delayed the onset of AIDS 
in HIV-infected individuals as well as reduced almost all opportunistic infections. The 
                                                 
1 double-strength (DS) tablet contains 160 mg of trimethoprim and 800 mg of sulfamethoxazole, while 
single-strength (SS) contains 80 mg of trimethoprim and 400 mg of sulfamethoxazole. 
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incidence of TE was, with no exception, decreased from 3.9 cases per 100 person-years in the 
period before the availability of HAART to 1.0 case per 100 person-years in the HAART era 
(Sacktor et al, 1990; Abgrall et al, 2001). However, TE remained the most prevalent CNS 
disorder, accounting for one-fourth of all documented cases in both antiretroviral-treated  
 
Study Design 
[References] 
Drug Regimens Outcomes 
 
Significance 
Cohort study in 83 
AIDS patients 
comparing primary 
and secondary 
prophylaxis to prevent 
TE with follow up 
duration of 3-41 mo 
(median = 8 mo) 
[Köppen et al, 1992] 
Aerosolized Pentamidine  (AP) 
IAP: Primary prophylaxis 
IIAP: Secondary prophylaxis 
Fansidar 
(pyrimethamine/sulfadiazine PY/S)
Ib: Primary prophylaxis 
IIb: Secondary prophylaxis 
TE occurrence  
 73% in IAP  
 30.9% in IIAP  
 5% in IPY/S  
 2.3% in IIPY/S  
 
Fansidar (PY/S) was 
recommended for  use as 
prophylaxis when AIDS 
patients with ≤ 100 
cell/mm3 , if CD4 100-200 
/mm3 AP was 
recommended  
Retrospective study in 
155 AIDS patients who 
were referred to  
tertiary referral 
teaching hospital after 
PCP for following up 
of the TE complication 
within 3 year periods 
[Carr et al, 1992] 
TMP-SMZ: 60 patients received 
trimethoprim 160 mg + 
sulfamethoxazole800 mg Low-
dose i.e. 2 tab twice a week  
AP or P: Pentamidine (AP) and 17 
patients received intravenous 
Pentamidine (P)    
No TE occurred in  patient 
who received TMP-SMZ 
with 1,153 days follow 
up  
33% TE occurred in 
patients who received 
AP or P (95% CI, 19% - 
51%, P=0.008) and TE 
occurred even patients 
have already received 
prophylaxis for 460 days 
Low-dose TMP-SMZ was 
more effective (P<.008) 
than AP in preventing TE 
in 
HIV-infected patients 
with previous PCP 
Randomized trial in 
AIDS patients who 
had CD4 < 200 cell/mm3
with the 539 days 
follow up period  
[Girard et al, 1993] 
 
D/PY: 173 patients received Dapsone 
50 mg(D ) plus  Pyrimethamine 50 
mg (PY)  
AP: 176 patients received aerosolized 
Pentamidine 300 mg (AP)  
 
TE occurred 10.9% in D/PY 
gr. (19 out of 173) and 
18.2% in AP gr. (32 out 
of 176)  
Patients receiving AP had 
1.81 times higher risk 
of TE than those 
receiving D/PY (95%, 
CI; 1.12 – 2.94, p= 0.02) 
Patients infected by T. 
gondii, TE risk was 2.37 
times (95% CI, 1.3 -4.4, 
P =0.006) 
D/PY prevents first 
episodes of TE better, but 
more toxicity than AP (42 
patients discontinued 
D/PY while only 3 
patients stopped AP, 
p<0.001)   
Prospective study in 
278 AIDS patients who 
had CD4 <250 cell/mm3 
and follow up TE 
occurrence for 42-44 
wks   
[Torres et al, 1994] 
D: patients received Dapsone 100 
mg, twice  per wk  
AP: 176 patients received aerosolized 
Pentamidine 100 mg every 2 wk 
 
6 TE events occurring 
among those receiving 
AP, compared to none 
among those taking D 
(p = 0.01). 
 
D was more effective in 
the primary prophylaxis 
of TE and has the 
advantage of a lower cost 
and easier 
administration. 
Multicenter, double-
blind randomized 
clinical trial in 378 
AIDS patients who 
had CD4<200 cell/mm3 
with 2.5  yrs follow up 
period  [Jacobson et al, 
1994] 
PY: 264 patients received 
Pyrimethamine 25 mg (PY) trice 
per wk  
Placebo: 132 patients received 
placebo 
 
Patients received  PY had 
higher death  rate (RR, 
2.5; 95% CI, 1.3-4.8; 
p=.006) 
No difference between two 
groups of TE 
occurrence, this  may 
be due to concomitant 
PCP prophylaxis with 
TMP-SMZ in both 
groups 
PY had bone marrow 
toxicity when patients 
received without 
leucovorin supplement 
will reduce the survival 
rate, thus primary 
prophylaxis for TE with 
PY was not 
recommended. 
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Study Design 
[References] 
Drug Regimens Outcomes 
 
Significance 
The placebo-controlled 
study, randomized, 
double-blind trial. 554 
HIV-infected patients 
who had CD4 < 200 
cell/mm3 were 
recruited in France, 
USA and Spain. 
[Leport et al, 1995] 
PY: 50 mg three time a week after a 
100-mg loading dose on the first 
day plus folinic acid 15 mg three 
time a week 
Placebo: the similar in appearance 
and taste to PY plus folinic acid 15 
mg three time a week 
TE occurrence  
 12% in PY gr. 
  13%in placebo  (RR 
0.9; 95% CI, 0.6-1.4),  
The survival rate was 
similar, 85% and 80% 
(RR, 0.9; 95% CI, 0.7-1.2). 
PY was not recommended 
as a primary prophylaxis 
of TE, but it should be 
considered for patients 
who are intolerant to 
TMP-SMZ, especially in 
high-risk patients with < 
100 CD4 cells/mm3. 
Randomized, open 
label, prospective trial 
in 197AIDS patients 
who had CD4<200 
cell/mm3 and no 
history of previous 
PCP or  TE [Antinori et 
al, 1995] 
AP: aerosolized Pentamidine 300 
mg/mo     
TMP-SMZ: trimethoprim 160 mg and 
sulfamethoxazole 800 mg every 
alternative day 
D/PY: dapsone-pyrimethamine 100 
mg/ wk  and  pyrimethamine 25 
mg every 2wk 
TE occurred  
 25.6/100 person-year in 
AP gr. 
 8.9/100 person-year 
inTMP-SMZ gr. 
 9.4/100 person-year in 
D/PY gr. 
  
Intermittent TMP-SMZ  
was more effective 
preventing TE than 
low-dose D/PY and 
AP  
D/PY was associated 
with a shorter 
survival.  
Case-control study in 
521 HIV-infection 
cohort study from 1993 
– 97  by selecting 32 TE 
cases compared with 
64 non-TE cases who 
were matched by CD4 
and Toxoplasma gondii
serostatus. [Ribera et 
al, 1999] 
Low doses TMP-SMZ:< 4 DS (8SS) 
tab/wk           (i.e. 3 DS tablets per 
week and 7 SS tablets per week) 
H igh doses TMP-SMZ: 14 DS/wk       
(7, 6, and 5 DS tablets per week). 
 
Patients receiving low dose 
TMP-SMZ had a higher 
risk of developing TE than 
those patients receiving 
high dose TMP-SMZ 
(estimated protective 
efficacy for high doses, 
89%). 
High doses of TMP-SMZ 
were more effective than 
low doses for lowering 
the risk of TE in HIV-
infected patients. Patients 
receiving concomitant 
rifampin treatment, 
rifampin may reduce the 
efficacy of TMP-SMZ. 
Table 2. (cont.) Data from the studies on toxoplasmic encephalitis during prophylaxis 
regimen period (1990-1997). AP = aerosol pentamidine, D = dapsone, DS = double-strength, 
gr. = group, mo. = month(s), P= pentamidine, PY/S = pyrimethamine/sulfadiazine, PCP = 
Peumocystis carinii pneumonia, RR = relative risk, SS = single-strength, Tab = tablet, TMP-
SMZ = trimethoprim + sulfamethoxazole, TE= Toxoplasmic Encephalitis, wk. = week(s)  
and untreated HIV-infected persons, especially among severe immunodeficients and in the 
absence of prophylaxis (Antinori et al, 2004). The significant risk factors for TE occurrence 
were identified as decreased CD4 count and lack of prophylaxis against infection with 
Toxoplasma species. As demonstrated by Abgrall and colleagues (2001), patients who 
discontinued TMP-SMZ prophylaxis, received before and after HAART period, had 4.8 and 
4.2 times increased risk of TE respectively. During HAART, patients whose CD4 cell counts 
increased to >200 cells/mm3, the incidence of TE was only 0.1 case/100 person-years (95% 
CI, 0.0–0.2) and TE was not increased even with the discontinuation of TMP-SMZ. On other 
hand, in HIV-infected individuals whose CD4 was lower than 50 cell/mm3, TE occurred in 
12.6/100 person-years, the most common opportunistic infection followed by PCP at 
11.4/100 person-years (Yazdanpanah et al, 2001). Other problems affecting TE occurrence 
even with the widespread use of HAART were patients unaware of their HIV serostatus and 
those who lacked exposure to HAART or prophylaxis. Thus they presented more with TE as 
AIDS defining illness than the pre HAART era. In cases who were accessible to HAART, the 
issues of patients’ adherence, drug resistance, failure and cross-resistance were major risks 
for the development of TE (Yazdanpanah et al, 2001; Antinori et al, 2004). 
The decreased incidence of TE and other OIs in HIV-infected patients from HAART raised 
the issue of discontinuation of primary prophylaxis preventing those OIs and secondary 
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prophylaxis against opportunistic diseases. Furrer et al (1999) demonstrated no case of P. 
carinii pneumonia (PCP) and TE in patients receiving a combined antiretroviral therapy and 
their primary prophylaxis were discontinued after CD4 increased to >200 cells/mm3 for at 
least 12 weeks, plus 14% of the total lymphocyte count. They also calculated the upper 99% 
confidence limits for the incidence of PCP at 1.93/100 patient-years, while it was 4.20/100 
patient-years for TE. They thus recommended stopping primary prophylaxis against PCP, 
but not TE, in HIV-infected patients who received HAART and had a sustained increase 
(longer than 12 weeks) in their CD4 counts to >200 cells/mm3 and to at least 14% of total 
lymphocytes. Because the number of TE patients who had been assessed were insufficient to 
recommend stopping prophylaxis, the same researcher group thus extended their study by 
accommodating more patients who were seropositive to T gondii with longer follow-up (up 
to 272 person-years) period. They reassured that stopping primary prophylaxis was safe in 
HIV- and T gondii-infected patients who responded to potent antiretroviral treatment with a 
sustained elevation in immunological markers (14% of peripheral lymphocyte count and the 
CD4 count remaining higher than 200 cell/mm3 for at least 12 weeks), especially in the 
regions where the prevalence of Toxoplasma infection was high as in central and western 
Europe (Furrer et al, 2000).  
Because of high toxicity, the discontinuation of secondary or maintenance prophylaxis of 
CMV infection and PCP were evaluated first and revealed safety discontinuing for patients 
receiving HAART whose their CD4 count was increased to >200 cells/mm3 (Zeller et al, 
2002). It was known that the risk of relapse after a TE episode was as high as 50% - 80% 
among patients who did not receive secondary/maintenance prophylaxis and survived 
more than 6-12 months (Miro et al, 2006). Studies were later undertaken to evaluate the 
safety of TE secondary/maintenance prophylaxis discontinuation. Concomitant results 
supported the recommendations of the US Public Health Service (USPHS) guidelines which 
suggested that secondary prophylaxis for TE can be discontinued for patients receiving 
HAART in whom either their CD4 counts remained >200 cells/mm3 for 3–6 months or CD4 
counts were >100 cells/mm3 with their plasma HIV RNA loads were <500 copies/mL 
(Soriano et al, 2000; Zeller et al, 2002). However, those studies were primarily aimed at 
evaluating PCP prophylaxis discontinuation in the patients’ CD4 threshold of <200 
cells/mm3. Miro and the GESIDA study group conducted a randomized, multicenter clinical 
trial by stratified HIV-infected patients according to the high risk of TE reactivation as CD4 
count of <100 cell/mm3. They found no episode of TE during a median follow-up of 25 
months (409 person-years). Thus, they recommended discontinuation of primary 
prophylaxis in patients with sustained increase in the CD4 count of >200 cell/mm3 for at 
least 3 months and advised to resume primary prophylaxis when the CD4 count was 
decreased to <100 cells/mm3 (Miro et al, 2006). This group also followed 20 patients who 
developed acute TE and received HAART. It revealed the majority of their T cell responded 
to T. gondii antigen, interferon (IFN)- production and CD4 count of >200 cell/mm3 were 
restored after at least 1 year of HAART. They concluded that the criteria for safely stopping 
TE secondary/maintenance prophylaxis should be when patients were on HAART for at 
least 1 year with an increase in CD4 count to >200 cell/mm3 and with totally (<5,000 
copies/mL) or partially (<10,000 copies/mL)  suppressed viral replication for at least 3-6 
months. Similar to primary prophylaxis, reintroducing secondary/maintenance prophylaxis 
whenever the CD4 count was decreased to <200 cell/mm3 was a prudent practice.  
It has been nearly 15 years since HAART was widely administered in advanced AIDS. Many 
benefits were well recognised and appreciated. However, there were reports of TE relapse 
after discontinuation of maintenance prophylaxis despite high CD4 count (Tsambiras et al, 
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2001; Ghosn et al, 2003). TE patients, from two large HIV centres in Germany, receiving 
HAART was studied regarding the restoration of T. gondii-specific immune response and 
IFN- as well as the longitudinal clinical characteristics/outcomes of TE (Hoffmann et al, 
2007). Patients were grouped according to the date of TE diagnoses i.e. period 1, 1990-1993; 
period 2, 1994-1996; period 3, 1997-1999 considered as early HAART period and period 4, 
2000-2004 as late HAART period (figure 2). The data from that study indicated several 
characteristics of TE  that have changed since the availability of HAART such as a marked 
increase in 5-year survival rate as 7% in period 1 compared to 78% in period 3 (p <0.0001). 
However, accumulative survival in the late HAART era was significantly lower than in the 
early HAART era (Figure 2). TE was found to be the first AIDS-defining illness more 
frequently than in earlier periods, therefore, patients who were co-infected with HIV and TE 
in HAART era did not receive antiretroviral therapy or any prophylaxis. More interestingly, 
persistent neurological deficits caused by TE such as hemiparesis, seizures, cognitive or 
other deficits were present in TE patients who survived during HAART higher than in pre 
HAART era (45% and 37%).  
 
 
Fig. 2. Comparing cumulative survival of toxoplasmic encephalitis (TE) patients during pre-, 
early- and late-HAART eras (Hoffmann et al, 2007)     
Hoffmann and colleagues found significant decrease in the T. gondii-specific immune 
response and IFN- (IL-12 and IL-15) in patients with acute episodes or relapses of TE more 
than in those who did not relapse even when maintenance therapy was discontinued. The 
latter was an adequate restoration group, while the former was a poor one in whom TE 
developed even on HAART and plasma HIV RNA level was below the detection limit for >6 
months and their CD4 count were >200 cell/mm3. There were evidences showing that 
functional immune restoration during HAART in advanced AIDS patients may be 
incomplete because quantitative increased CD4 count may not always reflect the quality of 
antigen-specific responses (Hoffmann et al, 2007; Furco et al, 2008). A multicentre study 
conducted by Spanish Toxoplasma gondii Study Group proposed whether in vitro lymphocyte 
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proliferative response (LPR) and IFN– production in response to T. gondii soluble antigen 
extract (SATg) could be used as a useful biomarker indicating immune restoration in AIDS 
patients receiving HAART. They found that severe immunosuppressed patients whose CD4 
count <200 cells/mm3 with experience in current or previous TE did not develop immune 
restoration indicated by almost absent of SATg-specific LPR and IFN-γ production. Those 
biomarkers were found in patients receiving successful HAART and in immnunocompetent 
asymptomatic patients who did not receive TE prophylaxis, however, they may be absent in 
HIV-1–uninfected and T. gondii-positive healthy subjects. Therefore, they cannot be used as 
biomarkers to detect the status of immune protection against T. gondii reactivation. 
Nevertheless, the discontinuation of TE prophylaxis, especially secondary prophylaxis, can 
be safely withdrawn after successful HAART as shown by CD4 count >200 cells/mm3 and a 
sustained reduction in viral load (Lejeune et al, 2011). 
3.3.1 Immune reconstitution inflammatory syndrome (IRIS) 
The administration of HAART in HIV-infected patients restores protective immune 
responses against a wide variety of pathogens and dramatically decreases mortality. An 
immune restoration process occurs by the suppression of HIV-1 viral replication followed 
by an increasing CD4 count. In some patients, however, during the initial institution of 
HAART, the restoration process may be complicated by immune reconstitution 
inflammatory syndrome or IRIS leading to worsening of clinical, laboratory and/or 
radiological features. Its histology showed an intense inflammatory reaction against intact 
subclinical pathogens or residual antigens of opportunistic infections and non-infectious 
agents. It occurs either by disclosure of occult subclinical infection or enhanced 
inflammatory response to a treated infection. The former is named “unmasking IRIS” while 
the latter is called “paradoxical IRIS”. About 10-25% of patients on HAART may develop 
IRIS, particularly in those patients with profound immune suppression, which may occur 
days to months after starting HAART, but normally within the first 2 months (Howard & 
Manji, 2009).  
The common neurological IRIS had been reported in cryptococcosis, tuberculosis, and 
mycobacteriosis (Murdoch et al, 2007). Despite TE being the most common opportunistic 
neurologic disease in HIV-infected patients, neurological IRIS associated with cerebral 
toxoplasmosis was rarely reported and has been doubted regarding insufficient clinical 
details challenging the diagnosis of IRIS. In contrast, Subsai and colleagues showed  that TE 
and other abnormalities such as stroke, progressive multifocal leukoencephalopathy (PML), 
and cytomegalovirus (CMV) retinitis were among the commonest kinds of neurological IRIS 
in northern Thai AIDS patients (Subsai et al, 2006). Their findings were TE-IRIS accounting 
for 0.29 and 0.59 per 100 person-years in the first and second year follow-up, respectively. 
Moreover, they found the incidence rate of TE-IRIS lower than the previous incidence 
during pre-HAART era. 
Sungkanuparpha and colleagues from 4 medical centres in Thailand reported one fatal case 
of toxoplasmosis after initial HAART institution in HIV-infected patient with very low 
median (range) CD4 count as 9 (0–147) cells/mm3. In their study, 20% developed 
unmasking OIs and tuberculosis was the most common followed by cryptococcal 
meningitis. They thus proposed that immune reconstitution response to occult pathogens 
may explain those phenomena (Sungkanuparpha et al, 2002). Researchers from Toulouse 
University, France reported 9 unmasking TE-IRIS cases; 3 out of 65 TE cases from their 
institution with a study period of 9 years and the 6 remaining cases from published 
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documents (Martin-Blondel et al, 2010). Their findings with other suggestion (Shelburbe et 
al, 2006) were proposed as a definition of unmasking TE-IRIS as 1) absence of neurological 
features related to TE in patients before starting HAART but presented afterwards; 2) at the 
onset of TE-IRIS, patients’ CD4 counts were higher than when starting HAART and their 
viral load were decreased > 1 log10; 3) histological features showed a profound 
inflammatory response with predominantly CD8 lymphocytes and 4) symptoms and signs 
were not due to other newly acquired infections, the expected TE course or drug toxicity.  
Paradoxical TE-IRIS cases, in which an exacerbation of a past known and usually treated TE 
occurred, were also reported (Pfeffer et al, 2009; Tremont-Lukats et al, 2009; Cabral et al, 
2010). Two HIV-infected known cases, without antiretroviral treatment, developed TE when 
their CD4 count was low. They thus received specific TE treatment and HAART and their 
immune status was restored as indicated by lowering of viral load and increased CD4 count. 
One and 3 months later, they presented with deterioration of clinical signs and symptoms 
related to TE. Imaging studies showed significant increase in size and stronger enhancement 
of the lesions as well as appearance of new nodular areas. Pathological study found an 
intense perivascular inflammatory infiltration, predominated by CD8 lymphocytes. One 
case (Pfeffer et al, 2009) showed both stages of cysts containing Toxoplasma bradyzoites and 
few tachyzoites, but negative in another (Cabral et al, 2010). Tremont-Lukats and colleagues 
(2009) reported a case of paradoxical TE, but was argued by another group (Martin-Blondel 
et al, 2009) because of finding abundant tachyzoites on brain biopsy, which is an active 
viable form of T. gondii, but not bradyzoite. Also, there was no evidence of an immune 
response of the affected tissues, so they suggested that the case might be due to an 
unfavourable course of a previously diagnosed toxoplasmosis than a TE-IRIS. 
Despite toxoplasmosis-associated IRIS being a very rare phenomenon, nevertheless, it 
occurs. Low metabolism of intracellular Toxoplasma bradyzoites with less expression of 
immunogenic surface proteins hides it from the host’s immunity, immune reconstitution 
during HAART is thus attenuated. The patients at highest risk are those with low CD4 
count, HAART-naïve, of young age and starting HAART close to a recent diagnosis of 
opportunistic infections (Shelburne et al, 2006). If TE-IRIS is suspected, close observation is 
recommended within 2 weeks. The use of magnetic resonance imaging in association with 
clinical and laboratory data can reduce the number of unnecessary cerebral biopsies (Cabral 
et al, 2010). A high steroid dose to control IRIS (Venkataramana et al, 2006), uninterrupted 
HAART, and ongoing treatment for toxoplasmosis could resolve the problem. 
4. Clinical features  
Toxoplasmic encephalitis (TE) is the most common cause of focal brain lesion (FBL) in 
HIV/AIDS individuals with profound immune deficiency. Clinical presentations of TE 
depended on the location, number and size of the lesions. It may present with generalized 
cerebral dysfunction or focal signs and symptoms of the central nervous system (CNS) or 
with psychiatric abnormalities (Table 3). The majority of patients present with a 
combination of generalized and focal CNS abnormalities (Table 1) such as headache, fever, 
alteration of consciousness, confusion, cognitive impairment, hemiparesis, facial nerve palsy 
and convulsion (Berger et al, 1987; Ragnaud et al, 1993; Wainstein et al, 1993, Sukthana et al, 
2000; Anrinori et al, 2004;  Nissapatorn et al, 2004b; Chankrachang, 2004; Miro et al; 2006; 
Hoffmann et al, 2007; Ho et al, 2008). Headache was a more frequent symptom than fever 
ranging from 47% to 100%, while fever was found 45.6% to 64.5%. However, Ragnaud and 
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colleagues (1993) demonstrated that fever was more sensitive than headache when used as 
diagnostic criteria (92% v. s. 41%sensitivity). 
TE has an insidious onset presenting initially by non-focal features such as headache, 
lethargy, cognitive impairment or confusion followed by focal neurological deficits which 
develop over a period of days to weeks (up to 4-6 weeks). The common focal neurological 
deficits are hemiparesis, ataxia and cranial nerve palsies (Mariuz & Steigbigel, 2001; 
Chankrachang, 2004). Convulsion was found to be the initial manifestations in 14%-39% of 
TE cases (Nissapatorn et al, 2004b; Chankrachang, 2004).            
 
Neurological manifestations Clinical presentations 
Generalized CNS dysfunction Alteration of consciousness 
 Confusion 
 Coma 
 Cognitive impairment 
 Stiffness of neck 
 Headache 
 Fever 
Focal neurological deficits Hemiparesis, hemiplegia 
 Convulsion 
 Cranial nerves deficit 
 Dysphasia, Aphasia, Dysarthria 
 Hemisensory deficit 
 Papilledema  
Psychiatric abnormalities Dementia 
 Anxiety 
 Psychosis 
 Personality changes 
Table 3. Neurological manifestations and clinical presentations of toxoplasmic encephalitis  
Neuropsychiatric abnormalities occasionally dominate the clinical picture (Mariuz & 
Steigbigel, 2001). Thus the diagnosis will be missed if those were not borne in mind. 
Meningeal involvement is rare, so that meningeal irritation is unusual on physical 
examination. However, nearly half of Thai TE patients had positive neck stiffness 
(Chankrachang, 2004; Mootsikapun et al, 2004). Diffuse form, without focal deficit, of TE 
showed rapidly progressive generalized cerebral dysfunction which was usually fatal. In 
such cases, histological study revealed numerous diffuse microglial nodules with T. gondii 
tachyzoites and cysts, hence brain CT scans were negative (Mariuz & Steigbigel, 2001). 
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Toxoplasmosis of the spinal cord is a rare manifestation and is usually associated with 
multiple lesions in the brain. Sites of involvement include the cervical, thoracic and lumbar 
spine. Few cases did not have brain lesions showing myelitis and myelopathic symptoms 
including a sensory level deficit, paraparesis, incontinence and changes in the deep tendon 
reflexes (Vyas, & Ebright, 1996; Kung et al, 2011). Kung and colleagues (2011) reported the 
first case of toxoplasmosis with myelitis in the absence of encephalitis and the diagnosis can 
be made pre-mortem by muscle biopsy showing multiple Toxoplasma bradyzoites and 
tachyzoites. Ajzenberg et al (2009) found a significantly higher TE occurrence in patients 
with AIDS than in patients whose immunosuppression was due to other causes than HIV 
infection (75% v.s. 27,8%). Patients with TE had a better outcome than those whose infection 
was non-cerebral, whereas pulmonary involvement was more frequently associated with 
death.    
5. Diagnosis  
There are no obvious or non-specific clinical manifestations of toxoplasmosis in competent 
hosts which are unique to the disease. Most of the time, infections are overlooked. Thus, it is 
not straightforward to diagnose. Serological testing in such patient is the main identifying 
evidence of specific antibody. In TE reactivation, clinical features are more helpful than 
serological testing in term of diagnostic criteria.  
Centre for Disease Control and Prevention (CDC), the National Institutes of Health, and the 
HIV Medicine Association of the Infectious Diseases Society of America recommend that 
making a definitive diagnosis of TE requires 1) compatible clinical features; 2) single or 
multiple mass lesions by computerized tomography (CT), magnetic resonance imaging 
(MRI), or other radiographic testing; and 3) the most important is detection of the organism 
in a clinical sample. This requires a brain biopsy performed by a stereotactic CT-guided 
needle biopsy. Organisms are demonstrable with hematoxylin and eosin stains and 
immunohistochemistry staining by experienced laboratories might increase sensitivity (CDC 
2009). However, these are always impracticable due to patients’ conditions. For clinically 
suspected TE cases, CDC criteria should be applied for a presumptive diagnosis i.e. 1) the 
recent onset of a focal neurological abnormality that is consistent with intracranial disease or 
reduced consciousness; 2) evidence from brain imaging of a lesion with mass effect and ring 
enhanced appearance after injection of a contrast medium; and 3) positive serum antibody 
to T. gondii or successful response to anti-toxoplasmic treatment (Sukthana, 2006). By using 
these presumptive diagnostic criteria, the positive predictive value is achievable in 
approximately 80% (Cohn et al, 1989; Katlama, 1992; Luft et al, 1993).   
On brain imaging, most of TE lesions occur in the basal ganglia, thalamus and 
corticomedullary junction (Lee et al, 2009). MRI is more sensitive than CT, Weenink and 
colleagues reported a TE patient who showed a normal contrast-enhanced CT scan, but MRI 
revealed clear abnormalities in the basal ganglia (Weenink et al, 2009). TE usually appears as 
multiple nodular or ring enhanced lesions with edema and mass effect. However, 14% of 
cases showing a solitary lesion which need to be differentiated from CNS lymphoma that 
more commonly presented as a single mass than toxoplasmosis (Legrand et al, 2010). 
Several techniques such as a diffusion weighted imaging; single-photon emission CT 
(SPECT) and positron-emission tomography (PET) could provide a more precise diagnosis 
(Sukthana, 2006; Legrand et al, 2010). Weighted MRI shows a peripheral hyperintensity of 
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TE mass lesion that is a feature helping to distinguish it from lymphoma. In comparison 
with TE and other infections, lymphoma displays high thallium uptake on SPET image. The 
rate of detection will be as high as 100% sensitivity and 89% specificity when the lesion is 
larger than 2 cm; otherwise it drops significantly if the lesion is smaller than 2 cm. PET 
imaging need more studies to determine its effectiveness (Lee et al, 2009). Among those 
techniques, none has high specificity and they are only useful when used in combination 
(Legrand et al, 2010). Moreover, they are costly and not widely available especially in 
resource-poor settings (Sukthana, 2006).  
Routine laboratory tests of the cerebrospinal fluid (CSF) are not helpful for TE diagnosis 
because they are usually normal or non-specifically altered. Increased protein level could be 
seen in about 65% of patients, low glucose level in 8-52% and pleocytosis, predominantly 
mononuclear cells, in 27-40% (Collazos, 2003). Intrathecal level of T. gondii antibody is 
always low and of limited value for diagnosis because its sensitivity and specificity is about 
60-70% (Collazos, 2003; Sukthana, 2006). Parasitic isolation from CSF is very rarely 
successful. Tachyzoites were seen in only 2 out of 6,090 examined ventricular CSF specimens 
and only 5 cases existed in the literature where a direct identification of T. gondii was 
possible by cytologic examination (Palm et al, 2008), however, those researchers reported a 
tachyzoites and bradyzoites of T. gondii directly seen in lumbar CSF cytology.  
Most patients with TE have an evidence of past infection showing a low titre of T. gondii 
antibody, but it helps the diagnosis. The absence of the antibody thus argues against TE 
diagnosis (Collazos, 2003; Sukthana, 2006). Nevertheless, it is not impossible since 3-5% of 
patients with TE have negative serological finding (Collazos, 2003). DNA-amplification-
based techniques greatly contribute to the diagnostic improvement. Blood PCR as a single 
test is not sensitive. CSF PCR produced disappointing results with low sensitivity (50%), 
although specificity is high (96%-100%) and the results usually are negative once specific 
anti-toxoplasmic therapy has been started (Collazos, 2003; Sukthana, 2006; CDC, 2009). 
Repeated testing and combining both CSF and blood PCR enhance sensitivity. Tachyzoite-
bradyzoite stage-specific primers could provide a more precise diagnosis of reactivated 
toxoplasmic encephalitis, especially in recurrent cases (Contini et al, 2002; Cultrera et al, 
2002; Mahittikorn et al, 2010). Sukthana used duplex reverse transcriptase PCR (RT-PCR) 
technique containing tachyzoite (SAG1) and bradyzoite (BAG1) specific genes developed by 
our colleagues (Mahittikorn et al, 2010) to diagnose Thai TE cases. It was found that RT-PCR 
technique is simple, easy to perform, and provides 85% positive predictive value when 
compared with CDC diagnostic criteria (to be published).  
6. Treatment   
The standard treatment of toxoplasmic encephalitis is a combination of pyrimethamine and 
sulfadiazine (PY+S). They provide synergistic action, pyrimethamine being an inhibitor of 
dihydrofolate reductase while sulfadiazine inhibiting dihydrofolic acid synthetase, an 
enzyme involved in folic acid metabolism. Dose-related bone marrow suppression, 
thrombocytopaenia and anemia by this combination could occur. Hence, oral folinic acid 
(leucovorin) is routinely given to prevent those effects without inhibiting the action of 
pyrimethamine (Petersen & Liesenfeld, 2007). Dose, duration and adverse effects of those 
drugs are shown in table 4. Serum levels of pyrimethamine on a dose of 25-75 mg/day 
ranging from 1 to 4.5 mg/l and its CSF level is 10-25% of the serum level. Sulfadiazine is 
well absorbed with good penetration into CSF (Petersen & Liesenfeld, 2007).  
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Treatment with PY+S has some limitations including 1) poor compliance due to side effects, 
particularly sulfadiazine; 2) the large number of pills needed; 3) unavailability in some 
countries; 4) high cost and 5) lack of an intravenous form. Nearly half of treated patients 
develop adverse effects such as gastrointestinal upset or rashes (Table 4) and require a 
change of therapy. Clindamycin is an alternative drug in the case of intolerance to sulfa- 
compounds. A 600 mg every 6 hours for 3-6 weeks by oral or intravenous route is 
recommended (Mariuz & Steigbigel, 2001; Sukthana, 2006; Dedicoat & Livesley, 2008). The 
efficacy and adverse effects of the combination between pyrimethamine and clindamycin 
(PY+C) seem to be comparable with pyrimethamine and sulfadiazine (PY+S) combination 
(Table 5). However, when using PY+C as a maintenance regimen, the relapse rate was twice 
higher (P = .02) than those who received PY+S (Katlama et al, 1996). Diarrheoa was more 
frequent on PY+C, while skin rash and fever were more commonly encountered in the PY+S 
group. More drug discontinuation occurred in the PY+S than in PY+C group (11 vs. 30%, 
p=.001). Therefore, Katlama et al (1996) suggested that a combination of pyrimethamine and 
clindamycin is a good alternative for acute treatment but is less effective for long-term 
prevention of the relapses.  
          
Drug Dosing/duration of treatment Adverse effects 
Pyrimethamine  
100 mg orally twice for 1 day, 
(loading dose) then 50-75 mg 
orally daily for 3-6 weeks 
Gastro-intestinal (GI) upset 
Rash 
Cytopaenias 
Sulfadiazine 
100 mg/kg (4-8 gm in four 
divided doses) orally daily for 3-6 
weeks 
GI upset 
Rash (including Stevens-Johnson 
syndrome) 
Cytopaenias 
Interstitial nephritis 
Crystalluria 
Encephalopathy 
Or 
Clindamycin 
600 mg every 6 hours for 3-6 
weeks, orally or IV use 
GI upset 
Rash 
Diarrheoa 
Pseudomembranous colitis 
Folinic acid 
10-20 mg orally daily for 3-6 
weeks 
 
Table 4. Recommended dose, duration and adverse effects of the standard and alternative 
drug regimens for toxoplasmic encephalitis (Modified from Mariuz & Steigbigel, 2001).  
Cotrimoxazole or trimethoprim-sulfamethoxazole (TMP-SMZ) is another regimen that has 
been studied and recommended as an alternative treatment in particular areas that 
pyrimethamine and sulfadiazine are not available especially in developing world (Torr et al, 
1998; Béraud et al, 2009). Its efficacy was as high as 70-85.5%, while the mortality rate was 
low (Table 5). TE relapse occurrence was around one-third of the patients and successfully 
re-treated by TMP-SMZ. Rash and neutropaenia were the most common side effects which 
occurred in 12-13.8% of patients but only half required treatment discontinuation. With its 
low cost, availability in parenteral form with excellent diffusion into the CNS and wide 
availability in developing countries, TMP-SMZ thus could be the first-line drug regimen for 
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curative treatment and prophylaxis of TE, especially in resource-poor settings (Torr et al, 
1998; Dedicoat & Livesley, 2008; Béraud et al, 2009). 
Atovaquone was studied as salvage therapy in AIDS patients with TE who were intolerant 
or failed PY+S or PY+C therapy (Torres et al, 1997). With a dose of 750 mg four times daily, 
52% and 37% of patients were clinically and radiologically improved during the acute-
therapy phase (the first 6 weeks), respectively, while 26% and 15% remained clinically or 
radiologically improved by week 18. Few patients’ adverse effects that were associated with 
and resulted in discontinuation of atovaquone were severe rash, fever, hepatomegaly, and 
toxic epidermal necrolysis. Commonly reported adverse events that did not result in 
discontinuation of therapy were fever, headache, diarrhea, nausea, and rash. 
 
 
Outcome 
Drug Regimen 
[Reference] 
PY+C 
 
[Mariuz & 
Steigbigel, 2001]
PY+C vs. 
PY+ S 
[Dedicoat & 
Livesley, 
2008] 
TMP-SMZ vs.
PY+ S 
[Dedicoat & 
Livesley, 
2008] 
TMP-SMZ 
 
 
[Bérau et al, 
2009] 
Mortality  rate 
6-20% 
during the first 
3 wk 
19% vs. 6%     
(RR 3.17,95% 
CI 0.67-15.06)
0% vs. 0% 3.2% 
Complete 
response 
clinical 
response 
18-55% 
46.2%vs. 
48.5% 
(RR 0.95,95% 
CI 0.55-1.64)*
 
70% vs. 70% 
(RR 1.0, 95% 
CI 0.74-1.33)*
 
85.5% 
neurological 
response 
71% by day 7  
and 
91% by day 14 
ND 
radiological 
response 
25% 
72-73% vs.    
61 - 80% 
68% vs. 62% ND 
Partial response 68-95% - - 
TE relapsed 
in 30% of 
patients 
Not response 5-12% ND ND 7.4% 
Adverse effect 40% 
60-62% vs. 
58-60% 
12% vs. 22% 
13.8%  (only 
7.4% 
required 
treatment 
interruption) 
Table 5. Outcome of TE cases after receiving different drug regimens therapy. *including 
complete or partial response defined as a resolution of TE or a greater than 50% 
improvement in the graded neurological examination. C = clindamycin; ND = no data; PY = 
pyrimethamine; S = sulfadiazine; TMP-SMZ = trimethoprim-sulfamethoxazole; vs. = versus; 
wk = week(s). 
6.1 Clinical response and outcome 
A complete response to standard therapy includes absence of neurological sequelae 
expected within 10-14 days. Luft and colleagues found that 50%, 86% and over 90% of 
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patients had a clinical response after 5, 7 and 14 days of treatment (Luft et al, 1993). 
Seizures and headache could not be used to assess the clinical response to therapy. 
Complete radiological response was defined as disappearance of all initial lesions and the 
absence of any new lesion. Those who showed clinical response, neuroradiographic 
abnormalities were also improved within 2-6 weeks in 91% (Mariuz & Steigbigel, 2001). 
Since patients may have more than one complication, follow-up brain imaging was 
recommended 10-14 days after starting therapy in each case (Chang et al, 1995). Brain 
biopsy should be considered in patients who clinically deteriorated after 3 days of 
treatment or showed no clinical improvement after 10-14 days of therapy. Treatment 
failure occurs if there is progression of either relevant symptoms and signs or new 
abnormalities developed within the first 10 days. Many patients died or still had 
neurological dysfunctions despite receiving standard or alternative therapy as well as 
developing adverse effects (Table 5).            
6.2 Maintenance (secondary) and primary prophylaxis  
Life-long maintenance/secondary prophylaxis, after acute-therapeutic phase, using half the 
dose of therapeutic drugs to prevent TE recurrence is necessary because the available drugs 
are ineffective against the tissue cyst that could later be reactivated (Sukthana, 2006). The 
use of highly active antiretroviral therapy (HAART) suppresses the HIV viral load and 
improves the CD4 count, followed by a strong reduction of opportunistic infections, 
including TE. It has been confirmed in randomized, controlled clinical trials that 
maintenance/secondary prophylaxis could be safely discontinued after HAART 
administration and immune restoration successfully occurred. Table 2 and sections 3.3 
entitled ‘TE during HAART period’ provide more details.  
HIV-infected patients with CD4 count <200 cell/mm3 and positive T. gondii antibody is 
indicated to receive primary prophylaxis preventing toxoplasmosis reactivation. Drug 
regimens, outcomes and recommendation provided in Table 2 and section 3.2 entitled ‘TE 
during prophylaxis regimen period’. Serological study identifying the past infection is 
prudent in HIV-infected individual, appropriate primary prophylaxis should thus be 
administered.      
7. Preventive measures   
Prevention of Toxoplasma infection comprise two important measures i.e. infected-meats 
and contamination by oocyst from cat excreta. HIV-infected persons with negative T. 
gondii antibody should be recommended to consume only well-cooked meats or those 
frozen for at least 24 hours. Properly cooked until the internal temperature is over 60C, 
correctly smoked or cured in the brine are safe, but microwave cooking is not (Mariuz & 
Steigbigel, 2001). Noteworthy, increasing animal-friendly production systems might 
increase T. gondii prevalence if cooking practice is not proper. Chumpolbanchorn et al 
(2009) demonstrated 64.03% T. gondii antibody in Thai free-range chickens, while low 
prevalence (2.3%) was found in animal-friendly pig production systems in the 
Netherlands (Kijlstra et al, 2004). 
Limiting exposure to cats, their litter and soil contamination with cat fecaes are things to be 
practised as well as avoiding infective oocysts by daily disposal cat litter and thorough hand 
washing, keeping cats indoor and feeding with canned or well-cooked food.      
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8. Conclusion   
Toxoplasmic encephalitis is the most common cause of focal CNS infections in people with 
AIDS. Its incidence has been reduced after prophylaxis was widely advocated, but the 
dramatic reduction occurred since HAART introduction. Although HAART restores 
immune status and improves the quality of life, some patients were complicated by immune 
reconstitution inflammatory syndrome (IRIS) with clinical and radiological deterioration. 
However, TE-IRIS rarely occurs. Clinical features of TE comprise focal and generalized CNS 
dysfunctions or with psychiatric abnormalities. Its insidious onset and clinical presentations 
depend on the location, size and number of focal lesions, which is usually multiple. The 
majority of cases were diagnosed presumptively including clinical relevance to CNS 
abnormalities, suggestive brain imaging and serological showing past T. gondii infection or 
response to anti-toxoplasmic therapy. Standard treatment is a combination of 
pyrimethamine and sulfadiazine for 3-6 weeks followed by either life-long maintenance 
prophylaxis or HAART to prevent TE relapse. Despite the efficacy of currently available 
drug regimens, the mortality and adverse effects continue to be problems for the responsible 
physician. Primary prophylaxis should be given to HIV-infected persons whose CD4 count 
is <200 cell/mm3 to prevent TE reactivation. HIV-infected individuals with negative T. 
gondii antibody should be instructed on preventing Toxoplasma transmission by avoiding 
either consuming infected meat or ingesting contaminated food and water by oocysts from 
cat excreta.              
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of the book is devoted to these viral pathogens, their epidemiology, pathology, diagnostics and molecular
mechanisms of encephalitis development by such viruses as HIV/SIV, herpes simplex virus type 1 and equine
herpesvirus 9, measles virus, coronaviruses, alphaviruses and rabies virus. The next section of the book
concerns the study of protozoan pathogens such as toxoplasma and amoebae. The last section of the book is
devoted to multicellular pathogen as human Filaria Loa Loa - a filarial worm restricted to the West Africa.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Yaowalark Sukthana (2011). Toxoplasmic Encephalitis, Non-Flavivirus Encephalitis, Dr. Sergey Tkachev (Ed.),
ISBN: 978-953-307-720-8, InTech, Available from: http://www.intechopen.com/books/non-flavivirus-
encephalitis/toxoplasmic-encephalitis
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
